文献速递类风湿关节炎

类风湿关节炎患者使用生物或靶向合成改善病情抗风湿药后的COVID-19结局

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs.
PubMed 文献 · RMD Open · 2023-01-01

研究基于美国TriNetX协作网络2018年1月1日至2022年12月31日数据,比较类风湿关节炎患者使用JAK抑制剂、IL-6抑制剂与TNF抑制剂(参照组)的COVID-19感染及不良结局。经倾向评分匹配后,JAK抑制剂组较TNF抑制剂组住院、死亡及复合不良结局风险显著升高,未接种COVID-19疫苗者死亡风险更高;IL-6抑制剂组未见上述差异。

要点

  • JAK抑制剂组较TNF抑制剂组住院风险显著升高(HR 1.194,95%CI 1.003至1.423)。
  • JAK抑制剂组较TNF抑制剂组死亡风险显著升高(HR 1.440,95%CI 1.049至1.976)。
  • 未接种COVID-19疫苗的JAK抑制剂组死亡风险趋于显著升高(HR 1.511,95%CI 1.077至2.121)。

核心结论

  • 类风湿关节炎患者使用JAK抑制剂者较TNF抑制剂者住院、死亡或复合不良结局风险显著升高,未接种COVID-19疫苗者死亡风险更高。
  • 作者建议在这些目标人群中鼓励接种COVID-19疫苗。
  • 作者认为临床医生使用JAK抑制剂时应警惕这些不良结局,以预防其发生或早期发现并早期干预。

研究设计与样本

  • 研究从美国TriNetX协作网络检索2018年1月1日至2022年12月31日的数据。
  • 研究比较类风湿关节炎使用JAK抑制剂、IL-6抑制剂与TNF抑制剂(参照组)的COVID-19结局。
  • 经倾向评分匹配后,JAK抑制剂组2676例对TNF抑制剂组2676例,IL-6抑制剂组967例对TNF抑制剂组967例。

主要发现

  • COVID-19感染发生率:JAK抑制剂组较TNF抑制剂组未达统计学显著(HR 1.058,95%CI 0.895至1.250)。
  • 住院风险:JAK抑制剂组较TNF抑制剂组显著升高(HR 1.194,95%CI 1.003至1.423)。
  • 死亡风险:JAK抑制剂组较TNF抑制剂组显著升高(HR 1.440,95%CI 1.049至1.976)。
  • 复合不良结局风险:JAK抑制剂组较TNF抑制剂组显著升高(HR 1.242,95%CI 1.051至1.468)。
  • 未接种COVID-19疫苗的JAK抑制剂组死亡风险趋于显著升高(HR 1.511,95%CI 1.077至2.121);IL-6抑制剂组较TNF抑制剂组未发现上述结果。

临床怎么用

  • 作者建议在这些目标人群中鼓励接种COVID-19疫苗。
  • 作者认为使用JAK抑制剂时应警惕这些不良结局,以预防其发生或早期发现并早期干预。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We aimed to investigate the role of rheumatoid arthritis (RA) with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD) exposure in COVID-19 outcomes. METHODS: Our study retrieved data from the US Collaborative Network in TriNetX between 1 January 2018 and 31 December 2022. We investigated b/tsDMARD use for RA: interleukin 6 inhibitor (IL-6i), Janus-associated kinase inhibitors (JAKi) or tumour necrosis factor-alpha inhibitors (TNFi, reference group). The outcomes of COVID-19 were the incidence of infection and adverse outcomes (hospitalisation, critical care services, mechanical ventilation and mortality). The HR and 95% CI of the outcomes were calculated between propensity score-matched (PSM) patients with different b/tsDMARDs. RESULTS: After PSM, 2676 JAKi vs 2676 TNFi users and 967 IL-6i vs 967 TNFi users were identified. As for COVID-19 incidence, JAKi users did not reach statistical significance (HR: 1.058, 95% CI: 0.895 to 1.250) than TNFi users. RA with JAKi users had a significant risk for hospitalisation (HR: 1.194, 95% CI: 1.003 to 1.423), mortality (HR: 1.440, 95% CI: 1.049 to 1.976) and composite adverse outcomes (HR: 1.242, 95% CI: 1.051 to 1.468) compared with TNFi users. Mortality risk tended to be significantly higher in the JAKi group without COVID-19 vaccination (HR: 1.511, 95% CI: 1.077 to 2.121). IL-6i users compared with TNFi users did not have the above findings. CONCLUSIONS: RA with JAKi users had a significant risk for hospitalisation, mortality or composite adverse outcomes, especially higher mortality among those without COVID-19 vaccination. COVID-19 vaccination should be encouraged in these target cohorts. When using JAKi for patients with RA, clinicians should be vigilant about these adverse outcomes to prevent their occurrence or detect them early for early intervention.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Tsai JJ, Liu LT, Chen CH, et al. COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs. RMD Open. 2023. PMID: 37479495. doi:10.1136/rmdopen-2023-003038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。